KR102655774B1 - 산-염기 장애의 치료를 위한 조성물 및 방법 - Google Patents

산-염기 장애의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102655774B1
KR102655774B1 KR1020187034960A KR20187034960A KR102655774B1 KR 102655774 B1 KR102655774 B1 KR 102655774B1 KR 1020187034960 A KR1020187034960 A KR 1020187034960A KR 20187034960 A KR20187034960 A KR 20187034960A KR 102655774 B1 KR102655774 B1 KR 102655774B1
Authority
KR
South Korea
Prior art keywords
meq
further example
delete delete
serum bicarbonate
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187034960A
Other languages
English (en)
Korean (ko)
Other versions
KR20180133931A (ko
Inventor
게리트 클라에너
에릭 에프. 코너
랜디 케이. 그버
매튜 제이. 케이드
폴 에이취. 키에르스태드
제리 엠. 바이세
마이클 제이. 코프
칼페쉬 엔. 비야니
손 에이취. 응우옌
스캇 엠. 타바크만
Original Assignee
트리시다, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트리시다, 인크. filed Critical 트리시다, 인크.
Publication of KR20180133931A publication Critical patent/KR20180133931A/ko
Application granted granted Critical
Publication of KR102655774B1 publication Critical patent/KR102655774B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
KR1020187034960A 2016-05-06 2017-05-05 산-염기 장애의 치료를 위한 조성물 및 방법 Active KR102655774B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662333059P 2016-05-06 2016-05-06
US62/333,059 2016-05-06
US201662350686P 2016-06-15 2016-06-15
US62/350,686 2016-06-15
US201662408885P 2016-10-17 2016-10-17
US62/408,885 2016-10-17
US201662414966P 2016-10-31 2016-10-31
US62/414,966 2016-10-31
PCT/US2017/031395 WO2017193064A1 (en) 2016-05-06 2017-05-05 Compositions for and method of treating acid-base disorders

Publications (2)

Publication Number Publication Date
KR20180133931A KR20180133931A (ko) 2018-12-17
KR102655774B1 true KR102655774B1 (ko) 2024-04-05

Family

ID=59315687

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034960A Active KR102655774B1 (ko) 2016-05-06 2017-05-05 산-염기 장애의 치료를 위한 조성물 및 방법

Country Status (15)

Country Link
US (6) US20200054669A1 (enExample)
EP (3) EP3831395A1 (enExample)
JP (3) JP7071284B2 (enExample)
KR (1) KR102655774B1 (enExample)
CN (2) CN116211887A (enExample)
AU (3) AU2017261337A1 (enExample)
BR (1) BR112018072714A2 (enExample)
CA (1) CA3023264A1 (enExample)
IL (2) IL308673A (enExample)
MA (3) MA54925A (enExample)
MX (1) MX2018013476A (enExample)
MY (1) MY197091A (enExample)
RU (1) RU2018142943A (enExample)
SG (1) SG11201809605PA (enExample)
WO (3) WO2017193064A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
KR20240008418A (ko) 2014-12-10 2024-01-18 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
AU2017261337A1 (en) 2016-05-06 2018-11-15 Tricida, Inc. Compositions for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
TW201922268A (zh) * 2017-10-16 2019-06-16 日商富士軟片股份有限公司 高磷血症治療劑及粒子
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
AU2018360868B2 (en) * 2017-11-03 2025-01-02 Tricida, Inc. Method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
EP3740201A4 (en) * 2018-06-04 2021-03-17 Tricida Inc. METHOD FOR TREATMENT OF ACID-BASE DISORDER
DK4053179T3 (da) 2021-03-01 2025-11-17 Renosis Inc Farmaceutiske sammensætninger med krydsbundne poly(allylamin)-polymer
MX2023010252A (es) 2021-03-01 2024-02-27 Renosis Inc Composiciones farmaceuticas de polimero de poli(alilamina) reticulado.
WO2023109825A1 (zh) * 2021-12-14 2023-06-22 上海石趣医药科技有限公司 氧化银和/或其水合物在制备药物中的用途
WO2023109826A1 (zh) * 2021-12-14 2023-06-22 上海石趣医药科技有限公司 碳酸银在制备药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094685A1 (en) * 2014-12-10 2016-06-16 Tricida, Inc. Proton-binding polymers for oral administration

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
CA2202397C (en) 1994-10-17 2002-07-16 Peter W. Stacpoole Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
WO1999040990A1 (en) 1998-02-17 1999-08-19 University Of Maryland Anion binding polymers and the use thereof
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
US20040059065A1 (en) 2000-03-09 2004-03-25 Takeshi Goto Crosslinked anion-exchange resin or salt thereof
AU2001241077A1 (en) 2000-03-09 2001-09-17 Hisamitsu Pharmaceutical Co. Inc. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
AU2001241095A1 (en) 2000-03-13 2001-09-24 Hisamitsu Pharmaceutical Co. Inc. Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
AT409630B (de) * 2000-12-13 2002-09-25 Dsm Fine Chem Austria Gmbh Alkylierung von n-bzw. amino- oder ammoniumgruppen haltigen, vernetzten polymeren
BR0209133A (pt) 2001-04-18 2004-06-15 Genzyme Corp Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
KR20040018357A (ko) 2001-04-18 2004-03-03 젠자임 코포레이션 저염 형태의 폴리알릴아민
BR0308316A (pt) 2002-03-11 2004-12-28 Novartis Ag Sais de nateglinida
JP2007523599A (ja) 2003-02-10 2007-08-23 オートゲン リサーチ ピーティーワイ エルティーディー． 治療用分子
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
AU2004311849B2 (en) 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
AU2004314652A1 (en) 2004-01-29 2005-08-11 Keio University Erythrocyte function modifying substance
EP1732523B9 (en) 2004-03-30 2010-06-02 Relypsa, Inc. Potassium binding polymers and uses thereof
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
EP2705849B1 (en) 2004-07-19 2018-04-04 N.V. Nutricia A preparation for use of aspartate for regulating glucose levels in blood
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
CA2613875C (en) 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
HUE025264T2 (en) 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
EP1951266A2 (en) 2005-09-02 2008-08-06 Genzyme Corporation Method for removing phosphate and polymer used therefore
US8586097B2 (en) 2005-09-30 2013-11-19 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
KR20080059265A (ko) 2005-09-30 2008-06-26 일립사, 인코포레이티드 포유동물의 위장관으로부터 칼륨 이온을 선택적으로제거하기 위한 방법 및 조성물
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN102600202A (zh) 2005-11-08 2012-07-25 味之素株式会社 麻醉苏醒促进剂
US20090162314A1 (en) 2005-11-08 2009-06-25 Huval Chad C Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
JP2009536246A (ja) 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
JP2009542653A (ja) 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
MX2009000611A (es) 2006-07-18 2009-04-16 Genzyme Corp Dendrimeros de amina.
EP2046284A1 (en) 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
WO2008027551A2 (en) 2006-09-01 2008-03-06 Genzyme Corporation Dendrimer compositions
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
CA2661987C (en) 2006-09-01 2012-11-06 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
EP2059247A1 (en) 2006-09-06 2009-05-20 Sucampo AG Method and composition for promoting gastrointestinal bicarbonate secretion
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
WO2008076242A1 (en) 2006-12-14 2008-06-26 Genzyme Corporation Amido-amine polymer compositions
JP2010519298A (ja) 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
EP2131820A1 (en) 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
WO2008133954A1 (en) 2007-04-27 2008-11-06 Genzyme Corporation Amido-amine dendrimer compositions
US8273384B2 (en) 2007-07-02 2012-09-25 Stephen Ray Wurzberger Process for the preparation of a non-corrosive base solution and methods of using same
KR20100045965A (ko) 2007-07-11 2010-05-04 도레이 카부시키가이샤 가교 폴리알릴아민 또는 그 산부가염 및 그 의약 용도
EP2016947A1 (en) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
WO2009023544A2 (en) 2007-08-10 2009-02-19 Ilypsa, Inc. Dosage unit anion-exchange polymer pharmaceutical compositions
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
EP2217215A1 (en) 2007-12-14 2010-08-18 Genzyme Corporation Coated pharmaceutical compositions
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
WO2009097127A1 (en) 2008-01-31 2009-08-06 Genzyme Corporation Pharmaceutical compositions
US20100035992A1 (en) 2008-03-11 2010-02-11 Rajiv Bhushan Methods and Compositions for Treating Inflammation and Inflammation-Related Pathologies
RU2010145166A (ru) 2008-04-08 2012-05-20 Юсв Лимитед (In) Способ получения соли аминополимера
US20110142952A1 (en) 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
CA2737452C (en) 2008-09-25 2018-05-22 Vive Nano Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
US20100113479A1 (en) 2008-10-30 2010-05-06 Anusuya Choudhury Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
CA2749397A1 (en) * 2009-01-22 2010-08-05 Usv Limited Pharmaceutical compositions comprising phosphate-binding polymer
WO2011059609A2 (en) 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
WO2011047700A1 (en) 2009-10-22 2011-04-28 Synthon B.V. Pharmaceutical compositions of sevelamer
WO2011071927A2 (en) 2009-12-07 2011-06-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP5865847B2 (ja) 2010-02-24 2016-02-17 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するための架橋されたポリビニルアミン、ポリアリルアミンおよびポリエチレンイミン
BR112012021448A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
IT1406068B1 (it) * 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
SG11201408521WA (en) 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients
EP2916851B1 (en) 2012-10-08 2025-12-17 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia
KR102633597B1 (ko) * 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
CN105873583A (zh) 2013-11-04 2016-08-17 凯克斯生物制药公司 用于降低慢性肾病患者的心力衰竭的枸橼酸铁
AU2017261337A1 (en) 2016-05-06 2018-11-15 Tricida, Inc. Compositions for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
AU2018360868B2 (en) 2017-11-03 2025-01-02 Tricida, Inc. Method of treating acid-base disorders
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP3740201A4 (en) 2018-06-04 2021-03-17 Tricida Inc. METHOD FOR TREATMENT OF ACID-BASE DISORDER
WO2019236639A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236124A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094685A1 (en) * 2014-12-10 2016-06-16 Tricida, Inc. Proton-binding polymers for oral administration

Also Published As

Publication number Publication date
US11992501B2 (en) 2024-05-28
JP7071284B2 (ja) 2022-05-18
IL308673A (en) 2024-01-01
IL262660B1 (en) 2023-12-01
EP3452028A4 (en) 2020-04-15
WO2017193050A1 (en) 2017-11-09
US11406661B2 (en) 2022-08-09
AU2023202111A1 (en) 2023-05-04
SG11201809605PA (en) 2018-11-29
JP2019514965A (ja) 2019-06-06
WO2017193064A1 (en) 2017-11-09
US20190134076A1 (en) 2019-05-09
CN109414453B (zh) 2023-02-17
WO2017193024A9 (en) 2018-11-22
US20210205351A1 (en) 2021-07-08
BR112018072714A2 (pt) 2019-02-19
AU2025217383A1 (en) 2025-09-04
WO2017193024A1 (en) 2017-11-09
JP2022106914A (ja) 2022-07-20
AU2017261337A1 (en) 2018-11-15
MA44875A (fr) 2019-03-13
US20190209607A1 (en) 2019-07-11
KR20180133931A (ko) 2018-12-17
CA3023264A1 (en) 2017-11-09
CN116211887A (zh) 2023-06-06
RU2018142943A3 (enExample) 2020-08-10
CN109414453A (zh) 2019-03-01
EP3452028A1 (en) 2019-03-13
RU2018142943A (ru) 2020-06-08
MX2018013476A (es) 2019-03-28
US20220062328A1 (en) 2022-03-03
US20250009785A1 (en) 2025-01-09
AU2023202111B2 (en) 2025-05-15
IL262660A (en) 2018-12-31
MA54925A (fr) 2021-12-22
EP3831395A1 (en) 2021-06-09
MY197091A (en) 2023-05-24
US20200054669A1 (en) 2020-02-20
IL262660B2 (en) 2024-04-01
EP3452057A1 (en) 2019-03-13
MA44886A (fr) 2019-03-13
JP2025157428A (ja) 2025-10-15

Similar Documents

Publication Publication Date Title
KR102655774B1 (ko) 산-염기 장애의 치료를 위한 조성물 및 방법
JP2022107004A (ja) 経口投与用プロトン結合ポリマー
US20250025494A1 (en) Compositions for and method of treating acid-base disorders
US20250222021A1 (en) Method of treating acid-base disorders
CA3102765A1 (en) Method of treating acid-base disorders
WO2019236124A1 (en) Method of treating acid-base disorders
HK40055721A (en) Compositions for treating acid-base disorders
NZ787487A (en) Compositions for and method of treating acid-base disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211121

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220929

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230829

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240111

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240403

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240403

End annual number: 3

Start annual number: 1

PG1601 Publication of registration